Fidelity Investments
TRDA icon

Fidelity Investments’s Entrada Therapeutics TRDA Stock Holding History

Fidelity Investments’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$214K Buy
16,943
+121
+0.7% +$1.39K ﹤0.01% 3469
2025
Q4 		$173K Sell
16,822
-15,124
-47% -$127K ﹤0.01% 3501
2025
Q3 		$185K Sell
31,946
-464,183
-94% -$2.72M ﹤0.01% 3381
2025
Q2 		$3.33M Sell
496,129
-743,682
-60% -$5.98M ﹤0.01% 2309
2025
Q1 		$11.2M Sell
1,239,811
-160,105
-11% -$2M ﹤0.01% 1868
2024
Q4 		$24.2M Sell
1,399,916
-343,582
-20% -$6.22M ﹤0.01% 1657
2024
Q3 		$27.9M Sell
1,743,498
-85,667
-5% -$1.35M ﹤0.01% 1597
2024
Q2 		$26.1M Buy
1,829,165
+1,661,244
+989% +$23.6M ﹤0.01% 1555
2024
Q1 		$2.38M Sell
167,921
-367,602
-69% -$5.2M ﹤0.01% 2286
2023
Q4 		$8.08M Sell
535,523
-46,593
-8% -$690K ﹤0.01% 1924
2023
Q3 		$9.2M Buy
582,116
+179
+0% +$2.82K ﹤0.01% 1846
2023
Q2 		$8.81M Buy
581,937
+50,529
+10% +$696K ﹤0.01% 1905
2023
Q1 		$7.71M Buy
531,408
+27,497
+5% +$367K ﹤0.01% 1969
2022
Q4 		$6.81M Buy
503,911
+4
+0% +$70 ﹤0.01% 2030
2022
Q3 		$7.94M Sell
503,907
-441,001
-47% -$5.6M ﹤0.01% 1999
2022
Q2 		$11.5M Buy
944,908
+68,114
+8% +$517K ﹤0.01% 1905
2022
Q1 		$8.23M Buy
876,794
+590,994
+207% +$6.34M ﹤0.01% 2196
2021
Q4 		$4.89M Buy
+285,800
New +$6.93M ﹤0.01% 2370

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments's TRDA Position: Q1 2026 in Review

Fidelity Investments increased its Entrada Therapeutics (TRDA) stake by 0.72% in Q1 2026, buying an estimated $1.39K and bringing the position to 16,943 shares worth $214K. The position accounts for ﹤0.01% of the portfolio, ranked #3469.

Fidelity Investments first reported a position in TRDA in Q4 2021 and has held it in 18 quarters since. The position peaked at $27.9M in Q3 2024. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • Fidelity Investments held 16,943 shares of Entrada Therapeutics worth $214K as of Q1 2026.
  • Fidelity Investments bought 121 Entrada Therapeutics shares in Q1 2026, an estimated $1.39K.
  • Entrada Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #3469 holding.
  • Fidelity Investments first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Fidelity Investments's Entrada Therapeutics position peaked at $27.9M in Q3 2024.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.